| Expression pattern: |
UP |
| Associated gene: |
KBTBD7, DRD2 |
| Associated microRNA: |
miR-145-5p |
| Biological function: |
Promotes cabergoline resistance and proliferation in PRL-PitNET cells; transmits resistance via exosomes; attenuates cabergoline-induced autophagy and AKT inhibition. |
| Molecular mechanism: |
Acts as a ceRNA by sponging miR-145-5p to upregulate KBTBD7, which promotes DRD2 ubiquitination/degradation, attenuating cabergoline-induced autophagy and impairing AKT pathway inhibition; exosome-mediated transfer propagates resistance. |
| Biological pathway or process: |
autophagy (inhibits); PI3K/AKT (promotes); ceRNA regulation (promotes); ubiquitination (promotes); drug resistance (promotes); proliferation (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RNase R Treatment; RT-qPCR; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Transfection; CCK8; EdU Staining; Colony Formation Assay; Western Blot; Co-IP; IF (Immunofluorescence); Luciferase Reporter Assay; In Vivo Animal Model; IHC (Immunohistochemistry); H&E Staining; Bioinformatics Analysis; Microarray |
| Clinical significance: |
Plasma exosomal circOMA1 levels are elevated preoperatively and decrease after surgery; circOMA1 is described as a prognostic indicator/biomarker candidate in PRL-PitNET/PitNETs. |
| Description: |
circOMA1 is upregulated in cabergoline-resistant PRL-PitNET and in patient plasma exosomes. It promotes and transmits cabergoline resistance by sponging miR-145-5p, increasing KBTBD7 to enhance DRD2 ubiquitination/degradation, thereby weakening cabergoline-induced autophagy and AKT inhibition; it also enhances tumor cell proliferation under cabergoline treatment. |
| Confidence score: |
0.871 |